Skip to main
Vyra Peptides

Vyra Peptides: tesamorelin visceral fat research

The most useful question here concerns fat distribution. The HIV trials measured visceral fat, liver fat and the response of the growth-hormone system.

HIV visceral-fat trials

The five-trial meta-analysis published in 2026 gives tesamorelin a substantial human evidence base in HIV-associated lipodystrophy. Mean visceral adipose tissue change was -27.71 cm2 (95% CI: -38.37 to -17.06; P<0.001). Trunk fat fell by 1.18 kg, hepatic fat fraction by 4.28%, and lean body mass increased by 1.42 kg.

Those are several changes in body composition. A single weight-loss score would discard the key findings: the location and kind of tissue. The participants had HIV-associated lipodystrophy, and large trials have yet to establish equivalent fat-loss effects in the general population.

The pivotal trial in 412 adults with HIV found visceral fat changed by -15.2% with tesamorelin versus +5.0% with placebo. Triglycerides fell by 50 mg/dL versus an increase of 9 mg/dL with placebo. These are the specific findings behind the reputation.

GHRH receptor studies

Tesamorelin is a synthetic 44-amino-acid version of growth hormone-releasing hormone, GHRH. Its modification helps it resist breakdown by DPP-IV. At the pituitary, it stimulates the GHRH receptor and amplifies the body's pulsatile release of growth hormone; that response also raises the liver-produced growth factor IGF-1. The LiverTox tesamorelin monograph describes the compound and its approved use.

A mechanistic study in 13 healthy men gives this mechanism a human measurement. After two weeks, mean overnight growth hormone rose by 0.5 µg/L (P=0.004) and IGF-1 by 181 µg/L (P<0.0001), while fasting glucose and insulin-stimulated glucose uptake were not significantly affected.

I like this small study for the modest job it can do: demonstrate a hormone response over a short interval. A long-term claim about glucose safety would demand more than those two weeks.

A technician beside a clock and assay plates in a laboratory at night.
An imagined overnight laboratory scene, accompanying the study of growth-hormone pulses in healthy men.

Liver findings from JAMA

In the six-month JAMA trial, 50 antiretroviral-treated adults with HIV were assigned to tesamorelin or placebo. The visceral-fat treatment effect was -42 cm2 (P=0.005); hepatic lipid-to-water percentage fell by a net -2.9% (P=0.003).

The same participants supplied measurements of visceral and liver fat, which makes this more informative than assuming that every kind of fat changes together. The trial still leaves non-HIV liver disease outside its studied population.

Discontinuation follow-up

The 52-week program reported sustained visceral-fat reduction of -18% during continued treatment. Visceral fat reaccumulated after discontinuation.

The return of visceral fat lowers my confidence in accounts focused solely on the initial reduction. The response lasted during treatment, while the follow-up supplied evidence about its dependence on continued exposure. A report of the initial reduction alone leaves out an observed part of the outcome.

Tesamorelin safety

Tesamorelin's human safety profile is well characterized within its approved indication. Several cautions define the limits of that profile:

  • Approved only for HIV-associated lipodystrophy. The FDA indication is narrow: excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy. General visceral-fat reduction, non-HIV NAFLD, anti-aging, and cognitive applications are off-label and investigational [2].
  • Trial generalizability. All pivotal trials enrolled HIV-positive adults on antiretroviral therapy. Generalizability to non-HIV populations is mechanistically plausible but not validated by large RCTs [1].
  • Reaccumulation on discontinuation. Visceral fat reaccumulated within weeks of stopping treatment in the 52-week trial [5]. Benefits depend on continued dosing.
  • IGF-1 elevation and oncology caution. GH-axis stimulation raises IGF-1; active malignancy is a labeled contraindication and long-term oncologic-safety data beyond 52 weeks are limited [2].
  • Glucose monitoring. Modest glucose perturbation can occur; monitoring is warranted in individuals with prediabetes or dysglycemia, though dedicated T2D trials found no significant HbA1c change [5].
  • WADA prohibition. Tesamorelin is prohibited in sport under the WADA Prohibited List S2 category (peptide hormones, growth factors, related substances and mimetics) as a GHRH analogue, in- and out-of-competition [7].
  • Research-grade supply. Research-grade material sold for laboratory use lacks the purity, potency oversight, and sterility assurance of the pharmaceutical product.

Prescription access begins with an individual assessment, including when that assessment takes place by telehealth. Each tesamorelin request to Promise Peptides (mypromise.com) is examined by a U.S.-licensed clinician, who makes the prescribing decision; the medication needs a prescription, and some requests are declined. Access is limited to U.S. patients and varies by state and treatment. Compounded medications are not FDA-approved.

Tesamorelin and retatrutide together

The trials cited here provide no direct test of adding tesamorelin to retatrutide. Tesamorelin's GHRH-driven hormone response and retatrutide's laboratory evidence of triple-receptor agonism explain why the mechanisms differ. Clinical benefit and safety of the combination would need their own trial.

A useful combination trial would measure visceral fat directly and report adverse events alongside it. Until then, the tesamorelin and retatrutide comparison can describe the separate records, and the combination question can identify the missing evidence.